Streetbeat News

Analyst Ratings

FATE

Fate Therapeutics (NASDAQ:FATE) received mixed analyst ratings in the latest quarter, with an average 12-month price target of $7.75, indicating a significant increase from the previous $4.50. Analysts from Morgan Stanley, BMO Capital, Barclays, and Wedbush raised their price targets, reflecting a positive outlook on the company's performance. Despite a substantial decline in revenue growth (-87.02%) and challenges in ROA, Fate Therapeutics shows strong profitability with a high net margin (-2323.56%) and effective use of equity capital as evidenced by its ROE (-10.75%).

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 8:00 pm

CCO

Barrington Research analyst James Goss has reiterated an Outperform rating on Clear Channel Outdoor (NYSE:CCO) and maintained a price target of $2.5.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:49 pm

ESPR

Needham analyst Serge Belanger has reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:47 pm

SNOW

Piper Sandler analyst Brent Bracelin has reiterated an Overweight rating on Snowflake (NYSE:SNOW) and maintained a $250 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:45 pm

PAR

Needham analyst Mayank Tandon has reiterated a Buy rating on PAR Technology (NYSE:PAR) and increased the price target from $47 to $53.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 7:43 pm

TMDX

TransMedics Group Inc (NASDAQ:TMDX) reported a Q4 profit with revenue of $81.2 million, up 159% Y/Y, surpassing the consensus of $68.51 million. The growth was attributed to increased use of its Organ Care System (OCS) and new logistics services. EPS was $0.12, beating the expected loss of $(0.03). The company expects FY 2024 revenues of $360-$370 million, above the consensus of $330.23 million. Oppenheimer raised TMDX's price target from $92 to $105 with an Outperform rating, and William Blair maintains an Outperform rating, highlighting the company's strong Q4 results and promising outlook.

Portfolio Pulse from Vandana Singh

February 27, 2024 | 7:33 pm

DHR

VLTO

BMO Capital Markets analyst John P. McNulty initiated coverage on Veralto Corporation (VLTO) with an Outperform rating and a price target of $97, citing strong EPS growth potential in the next 2-3 years. Veralto, which spun off from Danaher Corp (DHR) and began NYSE trading in October 2023, is expected to leverage its high-margin businesses and significant free cash flow for M&A to support double-digit EPS growth. The company recently reported Q4 earnings that beat consensus estimates and anticipates flat Y/Y non-GAAP core sales for Q1 FY24 with adjusted EPS of $0.73-$0.78.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 7:15 pm

COHR

Coherent's (NYSE:COHR) short interest has increased by 40.07% since the last report, with 4.57 million shares sold short, representing 4.02% of its float. This indicates a bearish market sentiment, although it's higher than its peer group average of 3.66%. The article suggests that an increase in short interest can sometimes be bullish.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 7:15 pm

DPZ

UBER

J.P Morgan analyst John Ivankoe downgraded Domino's Pizza Inc (DPZ) to Neutral from Overweight, despite raising the forecast to $430 from $420, citing the stock is now fully priced. Meanwhile, BMO Capital Markets analyst Andrew Strelzik reiterated an Outperform rating on Domino's, raising the price target to $535 from $475, highlighting January promotions, weather benefits, and contributions from Uber Eats. Domino's is seen as a beneficiary of food cost deflation and is expected to see restaurant margin improvements and unit growth acceleration in 2024.

Portfolio Pulse from Nabaparna Bhattacharya

February 27, 2024 | 7:12 pm

EVER

EverQuote (NASDAQ:EVER) has received 8 analyst ratings in the last three months, showing a positive shift with 6 bullish and 2 somewhat bullish ratings. The average 12-month price target is $18.88, marking a 45.23% increase from the previous target of $13.00. Analysts from firms like JP Morgan, Needham, B. Riley Securities, Raymond James, and Craig-Hallum have raised their price targets, reflecting optimism about EverQuote's future performance despite its recent revenue decline of -46.71% and challenges in market capitalization, revenue growth, and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 7:00 pm